JPRN-UMIN000046002
Completed
未知
Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic pulmonary sarcomatoid carcinoma: a retrospective cohort study - Efficacy and safety of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic pulmonary sarcomatoid carcinoma: a retrospective cohort study
ConditionsPulmonary sarcomatoid carcinoma
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Pulmonary sarcomatoid carcinoma
- Sponsor
- Kobe University
- Enrollment
- 124
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\)Patients who chose not to participate in the study (2\)Patients who received ICI as previous therapy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A real-world study of efficacy and safety of Immune check point inhibitors in patients with non-small cell lung cancer harboring driver oncogene excepting EGFRJPRN-UMIN000049022orth East Japan Study Group870
Completed
Not Applicable
The usefulness of immune checkpoint inhibitors among lung cancer patients with driver gene mutantsung cancerJPRN-UMIN000040789Yokohama City University
Completed
Not Applicable
Efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer other than adenocarcinoma or squamous cell carcinoma: multicenter retrospective observational studyon-small cell lung cancer other than adenocarcinoma or squamous cell carcinomaJPRN-UMIN000037777Hamamatsu University School of Medicine60
Not yet recruiting
Not Applicable
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390
Active, not recruiting
Phase 1
Patient preference for administration of cancer immunotherapy via an elastomeric pump. A patient preference study and an economic analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy is an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2021-000058-24-NLErasmus MC Cancer Institute390